Aiman El Fassi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aiman El Fassi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Abdelilah Ghannam
Intensive Care Department, National Institute of Oncology, University Mohammed V in Rabat, Rabat 10100, Morocco
1 shared publication - Amine Souadka
Surgical Oncology Department, National Institute of Oncology, Mohammed V University, Rabat, Morocco
1 shared publication - Brahim Elahmadi
Faculté de Médecine et de Pharmacie de Rabat, Université Mohammed V de Rabat, Impasse Souissi, Rabat 10100, Morocco
1 shared publication - Halima Abahssain
Department of Oncology, Centre Hospitalier de Valenciennes, 59300 Valenciennes, France
1 shared publication - Mohammed Anass Majbar
Surgical Oncology Department, National Institute of Oncology, Mohammed V University, Rabat, Morocco
1 shared publication - Oussama Ssouni
Faculté de Médecine et de Pharmacie de Rabat, Université Mohammed V de Rabat, Impasse Souissi, Rabat 10100, Morocco
1 shared publication
Latest Publications
- Open Access
Chronic Post-Surgical Pain at 3 Months After Breast Cancer Surgery: Incidence, Predictors, and an Internally Validated Risk Model
Background/Objectives: Chronic post-surgical pain (CPSP) affects 25–60% of women after breast cancer surgery. Prospective data from the Middle East and North Africa (MENA) region remain scarce. This study estimated 3-month CPSP incidence in a Moroccan cohort, developed two internally validated prediction models, and quantified the mediated effects of regional anaesthesia and ketamine through prevention of severe acute postoperative pain. Methods: Prospective cohort of 862 women undergoing curative breast cancer surgery (Institut National d’Oncologie, Rabat; NCT04676438). CPSP was defined as a visual analogue scale (VAS) ≥ 3/10 AND Brief Pain Inventory (BPI) interference ≥ 3/10 at three months. Two logistic regression models were developed (Model A: 7 preoperative variables; Model B: 11 perioperative variables) and internally validated by 1000-bootstrap optimism correction. Counterfactual mediation analysis quantified effects mediated through severe acute pain. Results: CPSP incidence was 39.1% (95% confidence interval (CI) 35.9–42.4%), with 22.6% neuropathic-predominant. Model A showed limited discrimination (area under the curve (AUC) 0.58), with pain catastrophising as the dominant predictor. Model B demonstrated superior performance (AUC 0.694; Brier score 0.209) with net clinical benefit across the 15–55% range of clinically plausible decision thresholds. In counterfactual mediation analysis, an estimated 58.2% and 53.7% of the RA and ketamine effects, respectively, were mediated through severe acute pain, under the framework’s no-unmeasured-confounding assumption. Perioperative ketoprofen independently reduced chronification risk (adjusted odds ratio (aOR) 0.66). Conclusions: In this single-centre Moroccan cohort, 39% of women developed CPSP at three months. Two validated models enable risk stratification at distinct clinical decision points. Regional anaesthesia and ketamine were associated with lower CPSP risk, in a pattern consistent with mediation through prevention of severe acute pain under the model’s assumptions; ketoprofen was independently associated with lower chronification risk. These observational findings are hypothesis-generating and require confirmation before informing changes to analgesic protocols.
Open AccessChronic Post-Surgical Pain at 3 Months After Breast Cancer Surgery: Incidence, Predictors, and an Internally Validated Risk Model
Background/Objectives: Chronic post-surgical pain (CPSP) affects 25–60% of women after breast cancer surgery. Prospective data from the Middle East and North Africa (MENA) region remain scarce. This study estimated 3-month CPSP incidence in a Moroccan cohort, developed two internally validated prediction models, and quantified the mediated effects of regional anaesthesia and ketamine through prevention of severe acute postoperative pain. Methods: Prospective cohort of 862 women undergoing curative breast cancer surgery (Institut National d’Oncologie, Rabat; NCT04676438). CPSP was defined as a visual analogue scale (VAS) ≥ 3/10 AND Brief Pain Inventory (BPI) interference ≥ 3/10 at three months. Two logistic regression models were developed (Model A: 7 preoperative variables; Model B: 11 perioperative variables) and internally validated by 1000-bootstrap optimism correction. Counterfactual mediation analysis quantified effects mediated through severe acute pain. Results: CPSP incidence was 39.1% (95% confidence interval (CI) 35.9–42.4%), with 22.6% neuropathic-predominant. Model A showed limited discrimination (area under the curve (AUC) 0.58), with pain catastrophising as the dominant predictor. Model B demonstrated superior performance (AUC 0.694; Brier score 0.209) with net clinical benefit across the 15–55% range of clinically plausible decision thresholds. In counterfactual mediation analysis, an estimated 58.2% and 53.7% of the RA and ketamine effects, respectively, were mediated through severe acute pain, under the framework’s no-unmeasured-confounding assumption. Perioperative ketoprofen independently reduced chronification risk (adjusted odds ratio (aOR) 0.66). Conclusions: In this single-centre Moroccan cohort, 39% of women developed CPSP at three months. Two validated models enable risk stratification at distinct clinical decision points. Regional anaesthesia and ketamine were associated with lower CPSP risk, in a pattern consistent with mediation through prevention of severe acute pain under the model’s assumptions; ketoprofen was independently associated with lower chronification risk. These observational findings are hypothesis-generating and require confirmation before informing changes to analgesic protocols.